Jazz Pharmaceuticals plc (JAZZ) has a negative trailing P/E of -33.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.00%, forward earnings yield 11.98%. PEG 1.11.
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 16.6 | 0.76 | 3.51 | 4.43 | - |
| 2017 | 16.6 | 0.69 | 2.98 | 4.99 | - |
| 2018 | 16.6 | -1.99 | 2.70 | 3.93 | - |
| 2019 | 16.2 | 0.68 | 2.72 | 3.92 | - |
| 2020 | 38.5 | -0.72 | 2.51 | 3.89 | - |
| 2021 | -23.1 | 0.10 | 1.92 | 2.46 | - |
| 2022 | -44.5 | 1.27 | 3.23 | 2.72 | - |
| 2023 | 18.8 | -0.07 | 2.08 | 2.03 | - |
| 2024 | 13.6 | 0.35 | 1.86 | 1.87 | - |
| 2025 | -29.1 | 0.18 | 2.40 | 2.43 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $6.41 | $1.49B | $396.83M | 26.7% |
| 2017 | $7.96 | $1.62B | $487.85M | 30.1% |
| 2018 | $7.30 | $1.89B | $447.1M | 23.6% |
| 2019 | $9.09 | $2.16B | $523.37M | 24.2% |
| 2020 | $4.22 | $2.36B | $238.62M | 10.1% |
| 2021 | $-5.51 | $3.09B | $-328.95M | -10.6% |
| 2022 | $-3.42 | $3.66B | $-214.14M | -5.9% |
| 2023 | $6.10 | $3.83B | $414.83M | 10.8% |
| 2024 | $8.65 | $4.07B | $560.12M | 13.8% |
| 2025 | $-5.84 | $4.27B | $-356.15M | -8.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $23.94 | $22.15 – $26.00 | $4.44B | $4.39B – $4.49B | 10 |
| 2027 | $25.01 | $22.94 – $29.07 | $4.79B | $4.62B – $4.98B | 10 |
| 2028 | $26.70 | $20.10 – $32.75 | $5.18B | $5.16B – $5.2B | 4 |
| 2029 | $30.88 | $29.67 – $32.25 | $5.76B | $5.59B – $5.96B | 2 |
| 2030 | $31.98 | $30.74 – $33.40 | $6.02B | $5.84B – $6.22B | 2 |
